This article is more than 5 years old. Information may no longer be current.

IOPtima announces 12-month data from glaucoma laser trials in Mexico and India

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

RAMAT GAN, Israel — IOPtima's laser-based therapy for reducing IOP without penetrating the eye membrane proved safe and effective after a 12-month follow-up of human clinical trials in Mexico and India, the company announced in a press release.

"The long-term maintenance of the IOP reduction, compiled with the high safety profile, as demonstrated in our clinical studies, place IOPtima's system for glaucoma treatment in the first line of accepted glaucoma treatments," Dr. Joshua Degani, chief executive officer of IOPtima, said in the release.

Combined results showed an average reduction in IOP from 25.5 mm Hg to 14.6 mm Hg (43%). Data also showed that the procedure reduced the average number of glaucoma medications from 2.6 to 0.6. The procedure kept IOP below 18 mm Hg regardless of medication use in 95% of patients and under 18 mm Hg with no additional medications in 67% of patients, the release said.

IOPtima, a Bio-Light Life Sciences subsidiary, designed the carbon dioxide laser to ablate the scleral membrane to an optimal thickness that allows percolation of intraocular fluid, the release said.